Suchergebnisse
Suchergebnisse:
Paul Beavis is a researcher and group leader in cancer immunology and immunotherapy at Peter MacCallum Cancer Centre. He is interested in developing novel CAR T cell technology and CRISPR/Cas9 technology to enhance immune responses against solid cancers.
Paul Beavis is an Author and Illustrator of children's books.
316. 2020. Adenosine receptor 2A blockade increases the efficacy of anti–PD-1 through enhanced antitumor T-cell responses. PA Beavis, N Milenkovski, MA Henderson, LB John, B Allard, S Loi, ... Cancer immunology research 3 (5), 506-517.
Paul Beavis is a cancer immunologist who studies T cell biology and CAR T cell therapy. He has published numerous articles and grants on topics such as IKZF transcription factors, exhausted CD8 T cells, and CRISPR engineering of CAR T cells.
Written by Deano Yipadee & Illustrated by Paul Beavis - Published by Scholastic 2015-2021. I co-creator the Nee Naw series from 2015-21. Any Nee Naw books after 2021 I have no involvement in.
Assoc. Prof. Beavis completed his PhD at Imperial College London in 2010 and joined Peter Mac shortly thereafter to work in the Cancer Immunology Program. He formed an independent research group in 2018, where his team is focused on the development of novel cancer immunotherapies.
18. Mai 2020 · Darcy, Beavis and colleagues use T cells engineered to express the dendritic cell growth factor Flt3L to co-opt the host endogenous adaptive immune response and control experimental tumor models.
